Table 1.
Demographic and treatment information
| Survivors without ADHD Symptoms (n = 80) | Survivors with ADHD Symptoms (n = 25) | Neurodevelopmental ADHD (n = 178) | |||||
|---|---|---|---|---|---|---|---|
| M ± SD | N (%) | M ± SD | N (%) | M ± SD | N (%) | ||
| Age, y | 12.3 ± 3.56 | 11.1 ± 3.23 | 11.1 ± 3.33 | ||||
| Age at diagnosis, y | 6.2 ± 3.92 | 5.7 ± 3.86 | — | ||||
| Time since diagnosis, y | 5.8 ± 3.20 | 5.1 ± 3.73 | — | ||||
| Sex | |||||||
| Male | 42 (52.5) | 13 (52.0) | 114 (64.0) | ||||
| Female | 38 (47.5) | 12 (48.0) | 64 (36.0) | ||||
| Race | |||||||
| Caucasian | 52 (65.0) | 19 (76.0) | 98 (55.1) | ||||
| African American | 14 (17.5) | 5 (20.0) | 34 (19.1) | ||||
| Asian American | 5 (6.3) | — | 11 (6.2) | ||||
| Hispanic | 2 (2.5) | — | 5 (2.8) | ||||
| Biracial | — | — | 3 (1.7) | ||||
| Other | 6 (7.5) | — | 17 (9.6) | ||||
| Unknown | 1 (1.3) | 1 (4.0) | 5 (2.8) | ||||
| Brain Tumor Diagnoses | |||||||
| Medulloblastoma | 17 (21.3) | 3 (12.0) | — | ||||
| Ependymoma | 16 (20.0) | 2 (8.0) | — | ||||
| Low-grade glioma | 18 (22.5) | 4 (16.0) | — | ||||
| Other (eg, germinoma, craniopharyngioma) | 28 (35.0) | 16 (64.0) | — | ||||
| Treatment | |||||||
| Surgery | 64 (80.0) | 17 (68.0) | |||||
| Chemotherapy | 53 (66.3) | 18 (72.0) | |||||
| Cranial radiation therapy | 52 (65.0) | 14 (56.0) | |||||
| Craniospinal radiation | 26 (32.5) | 8 (32.0) | |||||
| Focal radiation ADHD inattentive symptoms | 26 (32.5) | 7 (28.0) | |||||
| Parent symptom count | 0.95 ± 1.31 | 6.04 ± 2.10 | 5.80 ± 2.35 | ||||
| Teacher symptom count | 0.96 ± 1.67 | 4.88 ± 3.31 | 3.80 ± 3.17 | ||||
Note: There were no significant differences in demographic or medical variables between the 2 brain tumor groups. Survivors of brain tumors without attentional symptoms were significantly older at time of evaluation than children with developmental ADHD (P = 0.025).